Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Background: Cancer is one of the leading causes of death worldwide. Over the years, a
number of conventional cytotoxic approaches for neoplastic diseases has been developed …

Abstract Treatment of lung cancer remains a challenge, and lung cancer is still the leading
cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but …

Chimeric antigen receptor (CAR) T cells have been highly successful in treating
hematological malignancies, including acute and chronic lymphoblastic leukemia. However …

Chimeric antigen receptor (CAR) T cell therapy has made tremendous strides in the arena of
hematological malignancies with approved therapies in certain leukemias, lymphomas, and …

T lymphocytes play crucial roles in adaptive immune responses to tumors. However, due to
different tolerance mechanisms and inhibitory effects of the tumor microenvironment (TME) …

Recently developed cancer immunotherapy approaches including immune checkpoint
inhibitors and chimeric antigen receptor T cell transfer are showing promising results both in …

Adoptive cell therapy (ACT) is a rapidly growing anti‐cancer strategy that has shown
promise in treating various cancer types. The concept of ACT involves activating patients' …

The recent success of chimeric antigen receptor (CAR)-T cell therapy for treatment of
hematologic malignancies supports further development of treatments for both liquid and …

Cancer immunotherapy approaches have emerged as novel treatment regimens against
cancer. A particularly interesting avenue is the concept of in situ vaccination, where …